<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04361617</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00065273</org_study_id>
    <nct_id>NCT04361617</nct_id>
  </id_info>
  <brief_title>Nuts and Oil Pilot Study</brief_title>
  <official_title>A Feasibility Study of Tree Nut and Extra Virgin Olive Oil Supplementation to Improve Cardiometabolic Health</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Metabolic syndrome is considered to be a state of prediabetes and is a major risk factor for
      cardiovascular disease. Dietary interventions involving extra virgin olive oil (EVOO)
      supplementation and tree nut consumption can improve cardiometabolic health and reverse
      metabolic syndrome. The goal of this exploratory study is to establish the feasibility of
      using a novel measure - epigenetic age - to motivate behavior change and improve
      cardiometabolic health in individuals with metabolic syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Metabolic syndrome (MetS) is a collection of at least three out of five cardiometabolic risk
      factors including abdominal obesity, hypertension, elevated blood glucose,
      hypertriglyceridemia, and low high-density lipoprotein cholesterol. MetS is a major risk
      factor for cardiovascular disease and is considered a state of prediabetes. Improving
      metabolic parameters through dietary, behavioral, and pharmacological interventions can
      improve or reverse MetS. For example, increased consumption of extra virgin olive oil (EVOO)
      and mixed nuts was shown to reduce cardiovascular event rates and reverse MetS in a 5-year
      study in Spain (PREDIMED study). However, lower levels of adherence to the PREDIMED
      intervention was found in participants with a higher number of cardiovascular risk factors,
      larger waist circumference, and lower physical activity levels at baseline. New strategies to
      convey one's risk of morbidity and mortality at the onset of a dietary intervention may
      improve intervention adherence, particularly among individuals meeting the criteria for MetS.

      A greater DNA methylation-based predicted age relative to chronological age, often referred
      to as &quot;epigenetic age acceleration&quot;, has been associated with many lifestyle factors,
      including physical activity and diet, as well as components of MetS, including obesity, blood
      pressure, HDL cholesterol and blood glucose levels.

      The investigators hypothesize that the majority of people with MetS have advanced epigenetic
      aging, and among those that have advanced epigenetic age, learning one's epigenetic age, and
      epigenetic age-based predicted risk of morbidity and mortality at the onset of a dietary
      intervention will improve participant adherence to the dietary intervention. Further, the
      investigators hypothesize that EVOO and tree nut supplementation in participants with MetS
      and advanced epigenetic age could help reverse MetS and potentially slow epigenetic aging.
      Therefore, the investigators plan to conduct a feasibility pilot study to:

        1. To determine the proportion of participants with MetS with epigenetic age acceleration

        2. To assess adherence to daily EVOO and tree nut consumption over a 4-week intervention in
           participants informed of their epigenetic age acceleration at baseline compared to the
           control group

        3. Qualitatively explore how participants perceive epigenetic age, and how participants'
           experiences would impact the feasibility of a larger clinical intervention in terms of
           challenges and motivators

        4. Compare epigenetic age acceleration before and after the 4-week intervention

      For this study the investigators will recruit ~50 individuals with MetS aged 35 years or
      older. An in-person assessment visit will be scheduled for a morning time and participants
      will be asked to be fasting and will be instructed to bring their medications to the visit.
      Candidates will review the informed consent document at an in-person screening with study
      staff prior to beginning their participation. For all participants providing informed
      consent, who were fasting and met the MetS criteria at the initial in-person assessment
      visit, collected blood samples will be used to calculate epigenetic age acceleration. Other
      measures to be collected include body weight, height, waist circumference, blood pressure,
      and questionarries about demographics, health history and health habits. All participants
      with positive epigenetic age acceleration will be invited to participant in the tree nut and
      extra virgin olive oil intervention and will be contacted to schedule a baseline intervention
      visit.

      At the baseline intervention visit, all participants will receive a 2-week supply of EVOO and
      tree nuts, including unsalted English walnuts, almonds or pistachios (approximately 3-day
      supply of each type). Participants will be asked to supplement their normal diets with these
      products and will be provided recipes and other information that will allow them to replace
      other foods with the nuts and oil. The investigators will ask participants to consume one
      ounce of tree nuts per day and two tablespoons of EVOO per day by incorporating these foods
      into their diet. Dietary adherence diaries will be given to measure incorporation of the
      study foods.

      Participants will be randomized to learn about their epigenetic age acceleration (arm 1) or
      not to learn about their epigenetic age acceleration (arm 2) in a 1:1 allocation at the
      baseline visit. Those in the intervention arm 1 that are to learn about epigenetic age
      acceleration will receive some educational materials and a brief description of epigenetic
      age acceleration.

      Another visit will be scheduled at the end of week 1 for additional diet counseling, to
      assess safety/potential side effects, to collect adherence diaries, and for participants to
      receive the final 2-week supply of EVOO and tree nuts. A follow-up phone call for compliance
      assessment and to answer participant questions will be conducted at the end of week 2. A
      final measurement visit will be scheduled for the end of week 4 for a morning time and
      participants will be asked to be fasting. At the final measurement visit, the same measures
      as listed in the in-person assessment visit will be performed and study questionnaires, with
      the exception of demographics and health history, will be distributed.

      After the intervention, 10 randomly selected participants of the intervention arm 1
      (participants informed of their advanced epigenetic age), will be selected for a 30-minute
      phone interview to qualitatively explore participants' perception of epigenetic age, and
      challenges and motivators for behavior change during the intervention. The open-ended
      questions will be designed to ascertain understanding of epigenetic age, and assess the
      challenges and motivators participants encountered during the intervention. All interviews
      will be audio-recorded.

      This feasibility study, incorporating epigenetic age estimates with a dietary intervention in
      individuals with MetS, is an initial step in building our understanding of 1) the
      relationship between MetS and epigenetic age, 2) how epigenetic age estimates may be
      perceived by patients at high risk for CVD, and 3) will provide preliminary longitudinal data
      examining the potential to slow epigenetic age acceleration predictions after a 4-week
      dietary intervention to provide feasibility for a larger future study.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Knowledge of intervention arm will not be given to research labs with samples</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants with MetS with epigenetic age acceleration</measure>
    <time_frame>In-person 1 day assessment visit</time_frame>
    <description>To characterize the relationship between MetS and epigenetic aging, we will examine epigenetic age acceleration prevalence among the 50 participants with metabolic syndrome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of days for which EVOO was taken</measure>
    <time_frame>4 weeks</time_frame>
    <description>Adherence for each participant will be measured as the proportion of days in 4 weeks for which EVOO was taken</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of days for which nuts were taken</measure>
    <time_frame>4 weeks</time_frame>
    <description>Adherence for each participant will be measured as the proportion of days in 4 weeks for which nuts were taken</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of days for which nuts and EVOO were taken</measure>
    <time_frame>4 weeks</time_frame>
    <description>Adherence for each participant will be measured as the proportion of days in 4 weeks for which both nuts and of EVOO were taken</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participant experiences interview</measure>
    <time_frame>After 4-week intervention</time_frame>
    <description>Qualitative interview with open-ended questions designed to ascertain participant understanding of epigenetic age, and assess the challenges and motivators participants encountered during the intervention. Will be assessed using qualitative analysis methods.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in epigenetic age acceleration</measure>
    <time_frame>In-person 1 day assessment visit vs. final 1 day visit after 4-week intervention</time_frame>
    <description>The investigators will compare epigenetic age acceleration before and after the 4-week intervention via DNA methylation test.DNA methylation profiles (beta-value, after adjustment chip and position effects) at 1,030 unique DNA methylation profiles will be used for epigenetic age acceleration predictions, using the DNA GrimAge predictor. The investigators will calculate predicted lifespan and regress predicted lifespan on chronological age to produce estimates of epigenetic age acceleration.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Epigenetic age knowledge arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Half of the intervention participants will be randomly selected to be informed of their epigenetic age before the intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No epigenetic age knowledge arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The other half of intervention participants will not be informed of their epigenetic age before the intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Daily consumption of tree nuts and extra virgin olive oil</intervention_name>
    <description>All participants will receive a 4-week supply of extra virgin olive oil and tree nuts, including unsalted English walnuts, almonds or pistachios (approximately 3-day supply of each type). Participants will be asked to include in their normal diets these products and will be provided recipes and other information that will allow them to replace other foods with the nuts and oil. We will ask participants to consume one ounce of tree nuts per day and two tablespoons of EVOO per day by incorporating these foods into their diet.</description>
    <arm_group_label>Epigenetic age knowledge arm</arm_group_label>
    <arm_group_label>No epigenetic age knowledge arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and Women â‰¥ 35 years of age

          -  Metabolic syndrome, defined as &gt; 3 of the following:

        Waist circumference &gt;102 cm in men and &gt;88cm in women Triglycerides &gt;150 mg/dL HDL
        cholesterol &lt;40 mg/dL in men and &lt;50 mg/dL in women Systolic blood pressure &gt;130 mm Hg or
        diastolic blood pressure &gt;85 mmHg Fasting glucose &gt;100 mg/dL Willing to comply with study
        visits, as outlined in the protocol Able to read and speak English No allergies or
        hypersensitivities to olive oil or nuts

          -  Ability to understand and the willingness to sign a written informed consent document.

        Exclusion Criteria:

          -  Plans to move from the study area in the next 12 weeks

          -  Body Mass Index (BMI) &gt; 40 kg/m2

          -  Dementia that is medically documented or suspected, or clinical evidence of cognitive
             impairment sufficient to impair protocol adherence

          -  Candidate with any dietary practice, behavior or attitude that would substantially
             limit ability to adhere to protocol

          -  Homebound for medical reasons

          -  Living in the same household with another participant

          -  Insulin-dependent Diabetes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lindsay Reynolds, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lindsay Reynolds, PhD</last_name>
    <phone>3367131134</phone>
    <email>lireynol@wakehealth.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mara Vitolins, DrPH, RDN</last_name>
    <phone>3367162886</phone>
    <email>mvitolin@wakehalth.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Wake Forest Baptist Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 22, 2020</study_first_submitted>
  <study_first_submitted_qc>April 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2020</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metabolic syndrome</keyword>
  <keyword>extra virgin olive oil</keyword>
  <keyword>tree nuts</keyword>
  <keyword>DNA methylation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There are no plans to make IDP available to other researchers</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

